Cheema Aamir Adnan, Teklinski Andrew Henry, Maria Viqar, Chilukuri Karuna, Frank John Joseph, Gosselin Marc Oliver
Department of Internal Medicine, Division of Cardiology, St. John Hospital and Medical Center, Detroit, MI 48236, USA.
J Interv Cardiol. 2006 Feb;19(1):99-103. doi: 10.1111/j.1540-8183.2006.00112.x.
We describe the case of an 86-year-old woman who presented with unstable angina. She was given heparin and eptifibatide, and she underwent percutaneous coronary intervention (PCI). Shortly thereafter, she developed acute profound thrombocytopenia (6,000 platelets/mm3), which resolved after the discontinuation of heparin and eptifibatide. Four months later, she presented again with unstable angina and underwent PCI. Soon after the procedure, she again developed acute profound thrombocytopenia (2,000 platelets/mm3). To our knowledge, acute profound thrombocytopenia due to eptifibatide treatment in the same patient at two different times has not been reported before.
我们描述了一位86岁女性患者的病例，该患者表现为不稳定型心绞痛。她接受了肝素和依替巴肽治疗，并接受了经皮冠状动脉介入治疗（PCI）。此后不久，她出现了急性严重血小板减少症（血小板计数为6000/mm³），在停用肝素和依替巴肽后血小板计数恢复正常。四个月后，她再次因不稳定型心绞痛就诊并接受了PCI。术后不久，她再次出现急性严重血小板减少症（血小板计数为2000/mm³）。据我们所知，同一患者在两个不同时间因依替巴肽治疗导致急性严重血小板减少症的情况此前尚未见报道。
